It has been shown that UVB irradiation induces expression of COX-2 and up-regulation of COX-2 plays a functional role in UVB tumor promotion. In this study, we examined the cis-elements in the human COX-2 promoter that may be responsible for the UVB induction of COX-2. Analyses with the COX-2 promoter region revealed that the cyclic AMP responsive element near the TATA box was essential for both basal and UVB induced COX-2 expression. This was further supported by studies using a dominant negative mutant of CREB, which strongly inhibited the activity of COX-2 promoter. Electrophoretic mobility shift assays indicated that CREB and ATF-1 were the major proteins binding to the COX-2 CRE. CREB and ATF-1 were phosphorylated upon UVB treatment, and SB202190, a p38 MAPK inhibitor, decreased the phosphorylation of CREB/ATF-1 and suppressed COX-2 promoter activity. In contrast, treatment with forskolin, an activator of adenylyl cyclase, led to phosphorylation of CREB and ATF-1 and activation of COX-2 promoter. Finally, enhanced binding of phospho-CREB/ATF-1 to the COX-2 CRE was observed after UVB induction. Thus, one signaling pathway for UVB induction of human COX-2 involves activation of p38, subsequent phosphorylation of CREB/ATF-1, and activation of the COX-2 CRE through enhanced binding of phosphorylated CREB/ ATF-1. Oncogene (2001) 20, 5164 ± 5172.
Introduction
Ultraviolet B (UVB) irradiation from sun exposure is thought to be the major cause of human nonmelanoma skin carcinoma (Staberg et al., 1983; Strickland, 1986) . One possible mechanism for UVB induced carcinogenesis involves its ability to induce prostaglandin formation. It is known that there is increased production of free arachidonic acid and prostaglandins following acute exposure of human keratinocytes to UVB irradiation (Buckman et al., 1998; Fischer et al., 1999) . These products may then promote tumor growth by inhibiting immune surveillance (Huang et al., 1998) , increasing cell proliferation (Sheng et al., 1998) and promoting angiogenesis (Tsujii et al., 1998) .
The synthesis of prostaglandins is dependent on the activity of phospholipase A 2 and cyclooxygenases (COX). In response to a variety of stimuli, phospholipase A 2 releases arachidonic acid from cellular membrane phospholipids. Then COX converts arachidonic acid to prostaglandin H 2 , the common precursor to all prostaglandins, thromboxane and prostacyclins (Smith, 1997; Smith and Dewitt, 1996) . There are two isoforms of cyclooxygenase: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is expressed constitutively in most cell types and is involved in regulation of renal and vascular homeostasis and protection of the gastrointestinal tract (Kam and See, 2000) . COX-2 has low basal expression in most tissues, but is induced by tumor promoters (Kujubu et al., 1991) , growth factors (Moatter and Gerritsen, 1992) , cytokines (O'Banion et al., 1996) and endotoxins (O'Sullivan et al., 1992) .
Several lines of evidence suggest a role of COX-2 in carcinogenesis. Studies in rodents indicate that nonsteroidal anti-in¯ammatory drugs (NSAIDs), which inhibit both COX-1 and COX-2, reduce carcinogeninduced intestinal cancer (Reddy et al., 1993 . Epidemiological studies also suggest that aspirin reduces the risk of colorectal (Smalley and DuBois, 1997) and breast cancers (Harris et al., 1996) . Studies with COX-1 and COX-2 knockout mice have further illustrated the role of COXs in skin (Langenbach et al., 1999) and intestinal cancers (Oshima et al., 1996) . De®ciency in either COX-1 or COX-2 reduces the number of intestinal polyps in the min mice and decreases the number of papillomas in a mouse skin initiation/promotion model (Langenbach et al., 1999) . However, COX-2, but not COX-1, was up-regulated in human and rodent intestinal tumors (Boolbol et al., 1996; DuBois et al., 1996; Eberhart et al., 1994) and in rodent skin papilloma (Oshima et al., 1996) , suggesting a more prominent role of COX-2 in tumorigenesis. Consistent with this proposal, COX-2 is also up-regulated by tumor promoting agents (Buckman et al., 1998; DuBois et al., 1994) , including UVB.
COX-2 has also been implicated in UVB induced skin carcinogenesis. UVB induced COX-2 expression in human skin (Buckman et al., 1998; Isoherranen et al., 1999) , and oral administration of selective COX-2 inhibitor, celecoxib, produced a decrease in the tumor number and multiplicity in UV-treated hairless mice (Pentland et al., 1999) . In view of the importance of COX-2 in UVB-induced tumorigenesis, we have begun to characterize the signaling pathway of UVB induction of COX-2 in human keratinocytes, HaCaT (Chen et al., 2001) . We found that UVB induced COX-2 expression at both mRNA and protein levels, and p38 MAP kinases played a major role in this process. In the current study, we examined the cis-elements in the COX-2 promoter responsible for UVB-dependent transcription, and the transcription factors modulating COX-2 expression following UVB irradiation in HaCaT.
Results
The CRE in the human COX-2 promoter is essential for both basal and UVB induced COX-2 expression Our previous studies indicated that UVB treatment induced expression of the COX-2 gene in HaCaT cells in a dose-dependent manner (Chen et al., 2001) . To analyse cis-elements that are responsible for the UVB induction of COX-2, we transfected HaCaT cells with constructs containing the luciferase gene driven by COX-2 promoter sequences. Figure 1a depicts the positions of NF-kB, NF-IL6 and CRE sites in the COX-2 promoter, which have previously been shown to regulate COX-2 expression in response to dierent stimuli. The construct, phPES2(71432/ +59), which contains a fragment starting from 71432 to +59, was induced by UVB at the dose of 250 J/m 2 (Figure 1b) , suggesting the UVB responsive cis-elements are probably located within this region. Constructs with deletions or site-speci®c mutations were then used to locate the UVB responsive elements. Deletion of the sequence up to 7124 did not signi®cantly aect the basal or UVB induced expression of constructs, suggesting that neither the NF-kB site nor the NF-IL6 site plays a role in the UVB induction of the COX-2 promoter. In contrast, deletion up to 752 dramatically decreased the basal expression and UVB induction of constructs, implying that the CRE site is essential for the basal and UVB induced expression of COX2 (Figure 1b ). This proposition was further supported by constructs containing site-speci®c mutations. While mutation of either the NF-kB site or the NF-IL-6 site did not aect the UVB induction of the COX-2 promoter, mutation of the CRE site decreased both basal and UVB induced expression (Figure 1c) .
A dominant negative CREB mutant blocks UVB induced COX-2 promoter activation
The importance of the CRE site in the induction of COX-2 promoter by UVB was also supported by experiments using a dominant negative mutant of CREB (CREB-m1), which contains a Ser133 to Ala mutation, and can not be activated through phosphorylation at this site. Co-transfection of CREB-m1 with phPES2(7327/+59) strongly inhibited UVB induced expression of the construct in comparison with co- HaCaT cells were transfected with 1 mg of wild-type COX-2 promoter luciferase construct (7327/+59) or mutant construct derived from 7327/+59, and 50 ng pRL-TK. KBM refers to a construct with a mutation at the NF-kB site; ILM refers to a construct with a mutation at the NF-IL6 site; CRM refers to a construct with a mutation at the CRE. After transfection, cells were allowed to recover for 18 h and treated with 250 J/m 2 UVB. Cells were harvested 12 h later and ®re¯y lucferase and Renilla lucferase activities in cellular extracts were measured. Reporter activities were presented as a ratio of ®re¯y over Renilla luciferase activity. Columns, means; bars, s.e.m; n=9 from three experiments transfection of parent vector (Figure 2a) . In contrast, an IkB mutant (IkB-m1), which blocks the activation of NF-kB pathway, only had a moderate eect on the UVB induction of the construct (Figure 2b ). Taken together, these experiments suggest a prominent role of the CRE site in the expression of the human COX-2 gene.
CREB and ATF-1 bind to the COX-2 CRE To identify transcriptional factors that bind to the COX-2 CRE, electrophoresis mobility shift assays were performed. Incubation of HaCaT nuclear extracts with the COX-2 CRE probe produced three major bands, all of which were completely competed by excess cold COX-2 CRE, but much less eciently by the mutant COX-2 CRE (CRM). The lower band could be competed by a consensus EBOX sequence, suggesting that it results from the binding of transcriptional factors to the EBOX sequence in this probe ( Figure  3a ). High concentration of cold TRE, which contains a consensus AP-1 site, also decreased the binding, indicating proteins that bind to the COX-2 CRE can also bind to the AP-1 site with relative low anity. In later experiments, 1 ng of Ebox consensus sequence was used to decrease the intensity of the lower band so that the two upper bands could be visualized better. The binding activity of HaCaT nuclear extracts to the COX-2 CRE did not change consistently upon UVB treatment (Figure 3b ). The upper two bands contained CREB as shown by supershift experiments using an anti-CREB antibody (Figure 4 ). In addition, an antibody against ATF-1 caused the clearance of the middle band, suggesting it also contains ATF-1. We were unable to produce supershift or clearance using antibodies against c-Jun, JunD, c-Fos, ATF-2. In contrast, the binding of HaCaT nuclear extracts to a probe containing the human collagenase AP-1 sequence was supershifted by antibodies against c-Jun, Jun D, cFos (Silvers et al., unpublished observation). It appears that the middle band contains CREB/ATF-1 dimer while the upper band contains CREB dimer or CREB dimerized with another member of the CREB family. The composition of complexes was not changed by UVB treatment. samples also binds to the COX-2 CRE. Initial experiments with an antibody against phospho-CREB/ATF-1 did not produce supershift or clearance. This could be due to several reasons, for example, only a small proportion of CREB/ATF-1 is phosphorylated by UVB treatment in HaCaT nuclear extracts. To solve this problem, we produced CREB using in vitro translation and phosphorylated it with protein kinase A (PKA). In vitro translated CREB formed a complex with the COX-2 CRE, which can be shifted with an antibody against CREB ( Figure 5a ). Treatment of in vitro translated CREB with PKA resulted in phosphorylation of CREB at Ser 133 as shown by Western blot using an antibody against phospho-CREB (data not shown). The phosphorylated CREB also formed a complex with the COX-2 CRE, which was further shifted by antibody against either CREB or phospho-CREB ( Figure 5a ). The supershift produced by the anti-phospho-CREB antibody is speci®c since it did not shift the band formed by non-phosphorylated CREB. In addition, the band formed by in vitro translated CREB co-migrates with the upper band formed with HaCaT nuclear extracts (Figure 5a ), suggesting that the upper band formed by HaCaT nuclear extracts contains a CREB dimer. Knowing that the anti-phospho-CREB antibody shifts the complex formed by in vitro translated, phosphorylated CREB, we speculated that in HaCaT nuclear extracts, phospho-CREB is contained within a complex with other proteins such as coactivator CBP/p300 preventing it from entering the gel or that the epitope recognized by the antibody is masked. To solve this problem, the reaction was heated at 658C for 5 min to destroy the potential interaction between phospho-CREB and co-activators. Indeed, this treatment resulted in supershift by the anti-phospho-CREB antibody. The supershifted band is more obvious in UVB treated samples than in control samples ( Figure  5b) . The antibody appears to be more ecient in changing the complex formed by CREB/ATF-1 (middle band) than the upper band, which is expected considering that this antibody recognizes the phosphorylated forms of both CREB and ATF-1.
UVB activates CREB/ATF-1 through phosphorylation via p38 MAP kinases
Since CREB and ATF-1 appeared to be the major transcriptional factors binding to the COX-2 CRE, we investigated the possibility that CREB and ATF-1 are responsible for the UVB-induction of the COX-2 promoter through the CRE site. First, we examined whether CREB and ATF-1 were activated by UVB using an antibody recognizing the activated, phosphorylated forms of CREB and ATF-1. UVB treatment at a dose of 250 J/m 2 increased the phosphorylation of CREB and ATF-1 as early as 1 h after the treatment, and the increase lasted until 10 h, Figure 4 CREB and ATF-1 bind to the human COX-2 CRE, and UVB treatment does not appear to alter the composition of binding complexes. Cells were mock treated or treated with 250 J/ m 2 UVB and crude nuclear extracts were prepared 8 h after treatment. Five mg of nuclear extracts were incubated with 32 Plabeled COX-2 CRE at room temperature for 20 min, followed by incubation for 30 min at room temperature with antibodies for cJun, CREB, ATF-2 and ATF-1. The amounts of antibody were 1 and 6 mg for c-Jun, ATF-2, ATF-1, and 1 and 3 ml for CREB. Similar experiments were also conducted using antibodies for cFos, JunD, and none of them produced clearance or a supershift whether antibodies were incubated for 1 h before the addition of probe or incubated for 30 min after the binding reaction Figure 5 Phospho-CREB/ATF1 binds to the COX-2 CRE. (a) Binding of in vitro translated and phosphorylated CREB to the COX-2 CRE. CREB was produced with Promega TNT transcription and translation system in 50 ml of reaction. Twenty-®ve ml of it was treated with 5000 U PKA for 1 h at 308C. For gel shift analyses, 2 ml of TNT quick master mix (TNT), or in vitro translated CREB (CREB), or PKA treated CREB (p-CREB) was used per lane. For supersh®t analyses, 1 ml anti-CREB (a p-CREB) or phospho-CREB (a p-CREB) was included. Incubation of TNT quick master mix with the COX-2 CRE generated two bands, one of which could be competed by the consensus Ebox sequence (labeled as Ebox). (b) Preheating of HaCaT nuclear extracts revealed the binding of phospho-CREB/ ATF-1 to the COX-2 CRE. 2.5 mg of nuclear extracts in the assay buer were heated at 658C for 5 min, chilled on ice, followed by 1 h incubation with 1 ml or 2 ml of anti-phospho-CREB on ice. The reactions were then carried out as described in the Materials and methods section then returned to basal level at 24 h (Figure 6a) . Treatment of cells with 5 mM SB202190, a dose that has been previously shown to inhibit p38 MAP kinases, but not ERK1/2 MAP kinases in HaCaT cells (Chen and Bowden, 1999) , decreased the phosphorylation of CREB and ATF-1, while treatment with 20 mM PD98059, an selective inhibitor for ERK1/2 pathway, did not have a detectable eect on the phosphorylation of CREB and ATF-1. The total level of CREB was not aected by UVB or drug treatment (Figure 6b ). Taken together, these experiments indicate that UVB treatment may activate CREB and ATF-1 through phosphorylation via p38 MAP kinases.
Inhibition of UVB induced p38 MAP kinases inhibits UVB induced COX-2 promoter activation
If activation of p38 MAP kinases and subsequent phosphorylation of CREB/ATF-1 are responsible for the UVB induction of COX-2 promoter, we predicted that inhibitor of p38 MAP kinases would have an inhibitory eect on the UVB mediated induction of the COX-2 promoter. In HaCaT cells stably transfected with phPES2(7327/+59), a construct containing the sequence from 7327 to +59 of the COX-2 promoter, treatment with 5 mM SB202190 did decrease UVB mediated induction of this construct (Figure 6c ).
Forskolin induces the expression of the COX-2 promoter through activation of pathways involving CREB/ATF-1 but not c-Jun
To further establish a correlation between the activation of CREB/ATF-1 and induction of the COX-2 promoter, we investigated the eect of forskolin, an adenylyl cyclase activator that activates CREB through phosphorylation by PKA, on the COX-2 promoter activity. The eect of forskolin on phPES2(ILM), which contains mutated NF-IL6 site, and phPES2(CRM, ILM), which contains mutations on both the NF-IL6 and CRE sites, were compared. Twenty-four hours after transient transfection, cells were treated with forskolin for 6 h. Forskolin induced about a twofold increase in the luciferase expression from phPES2(ILM), but did not change the expression from phPES2(ILM, CRM) (Figure 7a ). Western blot analysis showed that forskolin induced phosphorylation of CREB and ATF-1 rapidly, lasting about 2 h (Figure 7b ). In contrast, parallel experiments showed that forskolin did not induce detectable phosphorylation of c-Jun or the level of c-Jun (data not shown). Thus forskolin appeared to induce the expression of COX-2 promoter through activation of pathways involving CREB or ATF-1, but not c-Jun.
A c-Jun dominant negative mutant blocks UVB-induced AP-1 activity but not COX-2 promoter activity.
To determine if c-Jun is involved in the COX-2 induction as previous studies suggested (Wadleigh et al., 2000; Xie and Herschman, 1995) , we made use of a dominant negative c-Jun mutant that has been modi®ed by us. This mutant lacks both the transactivation domain and the ability to bind to the AP-1 sequence, thus inhibits AP-1 activity presumably by squelching the members of AP-1 family. Cotransfection of this plasmid inhibited the UVB induction of luciferase expression driven by a sequence containing one consensus AP-1 site (Figure 8a ). In contrast, this Figure 6 Suppression of p38 MAP kinase pathway decreases UVB-induced phosphorylation of CREB/ATF-1 and COX-2 transcription. (a) Time course for UVB-induced phosphorylation of CREB/ATF-1. Forty mg of whole cell lysates were resolved on 10% polyacrylamide gel and probed with an antibody recognizing both phospho-CREB and phospho-ATF-1. A parallel blot was probed with an antibody for total CREB. (b) Eect of p38 MAP kinase inhibitor SB202190 (SB) and MEK1 inhibitor PD98059 (PD) on the UVB-induced phosphorylation of CREB. Cells were pretreated with 5 mM SB202190 or 20 mM PD98059 in serum-free medium for 1 h, then irradiated with 250 J/m 2 UVB or mock treated. After UVB treatment, cells were again cultured in serumfree medium containing inhibitors and harvested 5 h later. (c) Eect of SB202190 (5 mM) on COX-2 transcription. Cells with stable transfection of COX-2 promoter luciferase construct (7327/+59) were cultured to near con¯uence and serum-starved for 24 h. Cells were then treated with DMSO or SB202190 for 1 h in serum-free medium. Cells were then exposed to 250 J/m 2 UVB or mock-irradiated. After UVB irradiation, cells were treated with inhibitor again for 12 h and harvested. The cell lysates were prepared and COX-2 transcription was measured by quanti®ca-tion of luciferase activity Role of CRE in UVB induction of cyclooxygenase-2 Q Tang et al mutant did not decrease COX-2 promoter activity ( Figure 8b ). Since either deletion of the transactivation domain or the mutation on the DNA binding domain of c-Jun has been shown to inhibit the AP-1 activity induced by overexpression of c-Jun (Alani et al., 1991; Brown et al., 1996) , these data suggest that c-Jun does not play a role in the UVB induction of COX-2. Taken together, this series of experiments indicate that UVB can activate the human COX-2 promoter via the CRE through a pathway that involves p38 and CREB.
Discussion
Our previous work with the human keratinocyte cell line, HaCaT, indicates that UVB induces expression of COX-2 at both protein and messenger RNA levels (Chen et al., 2001) . In the present work, we have extended our observations by analysing the regulation of the activity of COX-2 promoter by UVB in HaCaT cells. Our results clearly show that COX-2 promoter activity is induced by UVB. Deletion as well as sitespeci®c mutation analyses of the COX-2 promoter indicate that the CRE site locates between nucleotides 756 and 752 is essential for basal and UVB induction of COX-2 transcription. This CRE site in the COX-2 promoter is necessary for the induction of COX-2 transcription mediated by v-src (Xie and Herschman, 1995), serum, platelet derived growth factor (PDGF) (Xie and Herschman, 1996) , bile acids (Zhang et al., 1998) , lipopolysacharide (LPS) (Inoue et al., 1995) and cytoskeleton-interfering agents (Subbaramaiah et al., 2000a) . Other cis-elements such as NF-kB, NF-IL6, which are necessary for induction mediated by LPS and other stimuli (Inoue and Tanabe, 1998; Inoue et al., 1995) , do not appear to play a role in the UVB mediated COX-2 transcription. Thus, the CRE site in the COX-2 promoter plays a major role in UVB mediated induction of COX-2 transcription. This conclusion is further supported by experiments with a dominant negative CREB mutant, which completely blocks the COX-2 promoter activity. Although our CRE mutation also changes the adjacent Ebox site, the fact that the UVB-induced COX-2 promoter activity is extremely sensitive to this CREB dominant negative mutant strongly argues for a role of the CRE but not the Ebox element in the UVB mediated induction of COX-2. On the other hand, since deletion of the COX-2 promoter up to 7124 does not aect its induction by UVB, and the construct with the CRE mutation retains higher induction than the construct containing nucleotides 752/+59, it is possible that cis-elements in the region between 7124 and 752 may also contribute to UVB induction of COX-2 transcription. It has recently been shown that two NF-AT sites within this region play essential role in the regulation of the COX-2 expression in human T lymphocytes (Iniguez et al., 2000) , Whether they also play a role in the UVB mediated induction of COX-2 transcription in HaCaT cells needs further studies. Signi®cant eorts have been directed to determining transcription factors activating the COX-2 CRE. Our gel shift assays using a probe from the COX-2 promoter containing the CRE/Ebox sequence indicate CREB and ATF-1 are the major proteins that bind to the COX-2 CRE, while the binding of c-Jun, c-Fos, JunD, ATF-2 to the COX-2 CRE is not detectable. These results dier from those of studies using the murine COX-2 CRE (Xie and Herschman, 1995), or the human COX-2 CRE (Subbaramaiah et al., 2000b) in other types of cells. Studies mainly from Herschman's group with murine COX-2 promoter demonstrated c-Jun, but not the classical transcription factor CREB or ATF-2, mediates v-src, PDGF, serum induction of murine COX-2 expression through the COX-2 CRE Herschman, 1995, 1996) . This conclusion is based on the observation that overexpression of wild-type c-Jun augments COX-2 expression, while that of wild-type CREB blocks COX-2 expression. Furthermore, by the use of chimerical transcription factors and an altered DNA binding site, these authors demonstrated that the activation domain of c-Jun is able to activate the murine COX-2 CRE, while the activation domain of CREB is not. Using a dominant negative c-Jun mutant that lacks both the transactivation domain and the DNA binding ability, we could not ®nd any suppressive eect of this mutant on the activity of the COX-2 promoter, whereas it suppresses the UVB induced AP-1 activation. Since the same deletion of either transactivation domain or the DNA binding domain has been shown to inhibit c-Jun induced AP-1 activation (Alani et al., 1991; Brown et al., 1996) , this result suggests that in HaCaT cells, cJun is not responsible for the UVB induction of COX-2 transcription through the CRE. In contrast, there appears to be a correlation between CREB/ATF-1 phosphorylation and COX-2 promoter activity in HaCaT cells. UVB treatment induces the phosphorylation of both CREB and ATF-1, which is dependent on the activity of p38 MAP kinase. Consistent with a role of p38 and phosphorylation of CREB/ATF-1 in the COX-2 promoter induction by UVB, we found that p38 inhibitor SB202190 has an inhibitory eect on UVB-induced COX-2 promoter activity. A stimulatory eect of CREB on the COX-2 promoter is also supported by studies using forskolin, a speci®c activator of protein kinase A that is able to phosphorylate and activate CREB at Ser133. In HaCaT cells, treatment with forskolin induces a transient phosphorylation of both CREB and ATF-1, and a 2 ± 3-fold induction of COX-2 promoter activity that is dependent on the COX-2 CRE. Interestingly, elevation of cellular level of cAMP also up-regulates the expression of endogenous COX-2 (Nusing et al., 1996; Oshima et al., 1991) . Thus, a correlation exists between the phosphorylation of CREB or ATF-1 and the COX-2 promoter activity.
Our previous study suggests that p38 MAPK is essential for UVB-mediated induction of COX-2 expression in HaCaT cells (Chen et al., 2001 ). This could be due to the stabilization of COX-2 mRNA (Dean et al., 1999; Lasa et al., 2000; Matsuura et al., 1999; Ridley et al., 1998) , or increased transcription of the COX-2 gene (Dean et al., 1999; Subbaramaiah et al., 2000a) as shown in other systems. The fact that the p38 MAPK speci®c inhibitor, SB202190, decreases COX-2 promoter activity suggests that p38 MAPK pathway also plays a role in the transcriptional induction of the COX-2 gene by UVB. It is noteworthy that inhibition of p38 MAPK activity does not lead to total suppression of UVB induction of COX-2 promoter activity, suggesting that other signaling pathways are also involved. The complete suppression of endogenous COX-2 expression at both mRNA and protein levels by the same dose of SB202190 would also argue for a role of p38 MAPK pathway in the COX-2 induction at posttranscriptional levels such as mRNA stabilization.
Previous work from this laboratory has shown that UVB induced AP-1 activation through a p38 MAPKdependent pathway (Chen et al., 1998; Bowden, 1999, 2000) . Since COX-2 expression is also dependent on p38 MAPK activity, a legitimate question is whether AP-1 activation contributes to UVB induction of COX-2 transcription. Using a dominant negative c-Jun mutant, we could not ®nd any suppressive eect of this mutant on the activity of the COX-2 promoter. However, it is not known how eective this mutant is in blocking the activity of other AP-1 family members. Thus the potential contribution of AP-1 activation to the COX-2 promoter activity has not been resolved in the present study and requires further investigation.
Taken together, these results suggest a major signaling pathway by which UVB induces COX-2 transcription involves activation of p38, phosphorylation of CREB/ATF-1, and increased binding of the phosphorylated CREB/ATF-1 to the COX-2 CRE.
Materials and methods

Plasmids
The phPES2 series of luciferase constructs containing wildtype or mutated human COX-2 promoter fragments were prepared and cloned into pGV-B (identical to pGL2 basic vector from Promega) (Inoue and Tanabe, 1998; Inoue et al., 1995) . The wild-type CREB (pCFCREB) and dominant negative mutant CREB (CREB-m1) were gifts from Marc Montminy (Salk Institute, San Diego, CA, USA). The dominant negative IkB mutant (IkB-m1) was a gift from Inder Verma (Salk Institute). TAM67, a c-Jun mutant that has the transactivation domain deleted (from 3 to 123 amino acid) was initially described in Alani et al. (1991) and subcloned into the EcoRI site of pcDNA3.1/His C (Invitrogen, Carlsbad, CA, USA) in this laboratory. An additional deletion (AA 256 ± 258) was introduced into the DNA binding site, using a QuickChange kit from Strategene (La Jolla, CA, USA). The introduced mutation in the DNA binding domain was initially described in Brown et al. (1996) . This plasmid was named TAM67D. Luciferase reporter construct driven by a 136-base pair fragment from the human collagenase-1 gene promoter (773 to +63) with one consensus AP-1 binding site was reported (Huang et al., 1996) .
Cells and transfections
The experiments were performed with human skin keratinocyte cell line HaCaT. These kertinocytes were derived from normal skin of a female patient and spontaneously immortalized (Boukamp et al., 1988) . They are near-doploid and form normal epidermis when transplanted to nude mice. Cells were cultured in DMEM supplied with 10% fetal bovine serum and penicillin/streptomycin. Transient transfections were performed using Lipofectamine Plus reagent (GIBCO, Rockville, MD, USA) according to the manufacturer's protocol. Brie¯y, cells were plated in 6-well plates the day before transfection and grown to about 90% con¯uence. One to 2 mg of plasmid DNA per well was prepared in 100 ml serum free DMEM and incubated with 3 ml of Plus reagent at room temperature for 15 min, followed by addition of 2.5 ml of Lipofectamine in 100 ml DMEM. After incubation at room temperature for another 15 min, the mixture was added into wells containing 0.8 ml DMEM. Transfections were allowed to proceed for 4 to 6 h and cells were washed twice and allowed to recover for about 18 h in DMEM before UVB or drug treatment. Transfection eciency was corrected by cotransfection of Renilla luciferase plasmid (Promega, Madison, WI, USA). The ratio between the reporter plasmid and Renilla luciferase plasmid was 20 : 1 for COX-2 reporters. For stable transfections, COX-2 reporters were co-transfected with pRSV/neo. After washing cells from transfection reagent, cells were grown in the complete medium to con¯uence, then transferred to a 100 mm dish and selected in 0.8 mg/ml G418 for 4 weeks before experiments.
UVB treatment
Cells were grown to 90% con¯uence and then serum starved for 24 h. Cells were then washed with phosphate buered saline and exposed to UVB radiation. A bank of two SF20 UVB lamps (National Biological Corporation, Twinsburg, OH, USA) providing a peak emission of 313 nm were used. Control cells were mock-irradiated. For drug treatment, drugs were added 1 h before UVB irradiation and continued after UVB irradiation until harvest.
Luciferase assay
After experimental treatments, cells were washed twice with cold PBS, lysed in a passive lysis buer provided in the dual luciferase kit (Promega), and assayed for luciferase activity according to the manufacturer's protocol. The data were presented as a ratio between Fire¯y and Renilla luciferase activities. The luciferase activity of cells with stable transfection of COX-2 reporters was assayed using a regular luciferase kit (Promega).
Western analysis
Cells were lysed in a buer containing 20 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 10 mM NaF, 50 mg/ ml aprotinin, 50 ug/ml leupeptin, and centrifuged at 14 000 r.p.m. for 10 min. Protein concentration in the supernatant was determined by BioRad D C reagent (Bio-Rad Laboratories, Hercules, CA, USA). For Western analysis, 30 to 40 mg of proteins were resolved on a 10% of SDS ± polyacrylamide gel. The proteins were transferred to a PVDF membrane by electroblotting. The membrane was then blocked in 5% nonfat dry milk TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween 20) at room temperature for 1 h. Primary antibody was diluted at 1 : 1000 in 5% BSA/TBST for antibodies against phospho-CREB, CREB, phopsho-c-Jun (New England Biolabs Inc., Beverly, MA, USA) or in 5% nonfat dry milk/TBST at 1 : 20 000 for anti-c-Jun antibody and at 1 : 4000 for anti-COX-2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membrane was incubated at room temperature for 2 ± 3 h and washed 365 min with TBST. The membrane was then incubated with corresponding horse radish peroxidase-conjugated secondary antibodies in 5% nonfat dry milk/TBST at room temperature for 1 h and washed 365 min with TBST. Antigen-antibody complexes were detected with LumiGlo reagent (New England Biolabs Inc.).
Electrophoretic mobility shift assays
The following sequences derived from the human COX-2 promoter containing the CRE (underlined) were used: PE2CRE1, 5'-GAAACAGTCATTTCGTCACATGG-3'; PE2-CRE2, 5'-CAAGCCCATGTGACGAAATGA-3'. They were annealed and 5'-overhangs were labeled by incorporation of [ 32 P]dCTP (NEN Life Science Products, Boston, MA, USA) with Klenow DNA polymerase. In addition, the following double oligonucleotides were also generated: CRM, containing mutations (underlined) in the COX-2 CRE: 5'-GAA-ACAGTCATTTCGCAACATGG-3'; and Ebox, which contains a consensus Ebox sequence: 5'CCCCCACCACGT-GGTGCCTGA-3'. For gel shift assays, 2 to 5 mg of nuclear protein extracts were incubated at room temperature for 5 min with a mixture containing 6 mM HEPES (pH 7.9), 0.4 mM EDTA, 125 mM KCl, 10% glycerol, 0.05 mg/ml poly dIdC, 1 mM DTT, 2.5 mM sodium pyrophosphate, 1 mM bglycerophosphate, 1 mM Na 3 VO 4 , 10 mM NaF, 50 mg/ml aprotinin, 50 ug/ml leupeptin. Approximately 1 ng labeled probe was added and the reactions were incubated at room temperature for another 20 min. In antibody supershift experiments, reactions were preincubated with various amounts of antibodies on ice for 1 h before the addition of probe. Reactions were then fractionated on a nondenaturing 5% polyacrylamide gel in 0.56TBE (16TBE=89 mM Tris base/89 mM boric acid/2 mM EDTA, pH 7.2). The gels were dried and visualized with Phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA).
In vitro translation and phosphorylation of CREB CREB was produced using the TNT Quick coupled transcription/translation systems (Promega) from 1 mg of pCFCREB plasmid DNA according to the protocol provided by the manufacturer. To phosphorylate CREB, a 25 ml aliquot of the reaction was incubated with 5000 U of recombinant PKA (New England Biolabs Inc.) at 308C for 1 h. Abbreviations UVB, ultraviolet B; COX-2, cyclooxygenase-2; COX-1, cyclooxygenase-1; CRE, cyclic AMP responsive element; CREB, CRE binding protein; AP-1, activator protein-1; MAP, mitogen-activated protein; ERK, extracellular signal-regulated protein kinase; p38, p38 MAP kinase; ATF-1, activating transcription factor
